- Home
- Equipment
- usa new york
- clinical trial
Show results for
Refine by
Clinical Trial Equipment Supplied In Usa New York
25 equipment items found
Manufactured by:Health Care Originals, Inc. based inRochester, NEW YORK (USA)
Health Care Originals (HCO) equips you to implement your study the way you envisioned, adapting to your needs. Our unobtrusive application, ambulatory cough monitoring, other symptom monitoring and low burden of use allow you to recruit with greater diversity. You can collect data at any point in the study, and we provide metrics as required to evaluate, keep participants engaged and ultimately ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety ...
Manufactured by:Zetagen Therapeutics Inc. based inSyracuse, NEW YORK (USA)
Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic ...
Manufactured by:SIGA Technologies, Inc. based inNew York, NEW YORK (USA)
SIGA has developed TPOXX® Injection, an intravenous (IV) formulation of TPOXX® for those patients who are too sick or unable to swallow oral capsules. SIGA completed clinical trials for the IV formulation with funding from the Biomedical Advanced Research and Development Authority (BARDA). In April 2021, SIGA submitted a New Drug Application (NDA) with ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
Previously, the EMA granted the MAA accelerated assessment status. In parallel, Stemline is evaluating ELZONRIS in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
We engineered INB-200 to be resistant to alkylating chemotherapy such that it can be used as an adjuvant with the current standard-of-care to drive improved anti-tumor response. The Phase 1 repeat dose escalation clinical trial of INB-200 is being conducted at the O’Neal Comprehensive Cancer Center at the University of Alabama at ...
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
Advancing a potent and selective Atopic Dermatitis treatment through the clinic. What is Atopic Dermatitis? Atopic Dermatitis (AD), the most common type of eczema, is a chronic relapsing inflammatory skin disease that results in itchy, red, swollen, and cracked skin. Our work : BEN-2293, a Pan-Trk antagonist, is being developed to treat AD without the need to use topical steroids ...
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
We identified baricitinib — a drug owned by Eli Lilly and approved to treat rheumatoid arthritis — as the strongest treatment candidate. Our hypothesis sparked global clinical trials and the drug we identified is now approved by the FDA to treat ...
Manufactured by:Laxxon Medical based inNew York, NEW YORK (USA)
Its engineering allows integration of patient safety features, like QR codes, directly onto drug surfaces, facilitating secure, information-rich pharmaceutical solutions. Furthermore, SPID Technology supports scalable production from clinical trials to mass production, accommodating up to 1.5 million units daily. This cold-process technology augments solubility, ...
Manufactured by:International Flavors & Fragrances (IFF) based inNew York, NEW YORK (USA)
Microencapsulated iron salt, High concentration (40% iron), High stability and no metallic taste, Reduced gastrointestinal side effects, High bioavailability confirmed by human clinical study, Approved health claims in Europe. Daily intake of iron is essential to avoid iron deficiency, the most prevalent nutritional deficiency. Iron deficiency or low iron levels can be prevented by increasing ...
Manufactured by:Vitalis, LLC based inNew York, NEW YORK (USA)
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for RRMS with fewer side effects and other clinical benefits for these ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1900, Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic ...
Manufactured by:Transluminal Technologies, LLC based inSyracuse, NEW YORK (USA)
A first-of-its-kind magnesium alloy-based vascular closure device that offers a unique method of quickly achieving stable mechanical vascular closure following percutaneous catheterization for diagnostic or interventional procedures using 5-8 Fr procedural sheaths. The implant consists of a plug and footplate system that when presented to the arteriotomy, effects immediate, stable and reliable ...
by:Curemark based inRye Brook, NEW YORK (USA)
The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug ...
Manufactured by:ENB Therapeutics based inNew York, NEW YORK (USA)
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which is required for T-cells to leave the circulation and infiltrate the tumor. Activated T cells are then able to infiltrate the tumor and kill ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-PAD cells exhibit regenerative potential due to their capacity to release factors in response to chemical distress signals from tissues that have been damaged by muscle trauma or inflammation. These therapeutic factors trigger the body’s repair mechanisms and stimulate tissue renewal, differentiation and modulation of immune-mediated inflammation. PLX-PAD cells also modulate the immune ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated delivery platform based on arenaviruses, a family of naturally-occurring ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
LAD-I is a rare genetic disorder affecting the immune system and is caused by a defect in the ITGB2 gene, leading to a deficiency in CD18. Due to this deficiency, white blood cells (primarily neutrophils) are unable to leave the bloodstream to go to the site of infection. As a result, patients with severe LAD-I can develop life-threatening infections which they are unable to fight. Without a ...